Does the oxidative stress in chronic obstructive pulmonary disease cause thioredoxin/peroxiredoxin oxidation?

Antioxidants and Redox Signaling

Volumn 10, Issue 4, 2008, Pages 813-819

  Lehtonen, Siri T ^a,b   Ohlmeier, Steffen ^a   Kaarteenaho Wiik, Riitta ^a,b   Harju, Terttu ^a,b   Pääkkö, Paavo ^a   Soini, Ylermi ^a,c   Kinnula, Vuokko L ^d  

^a UNIVERSITY OF OULU   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXIREDOXIN; THIOREDOXIN;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG BIOPSY; LUNG FUNCTION; LUNG HOMOGENATE; MASS SPECTROMETRY; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PEROXIREDOXINS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; THIOREDOXINS;

EID: 38949083243     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2007.1952     Document Type: Review

References (29)

1. Barnes PJ. Alveolar macrophages as orchestrators of COPD. COPD 1: 59-70, 2004.
2. Chang TS, Jeong W, Woo HA, Lee SM, Park S, and Rhee SG. Characterization of mammalian sulfiredoxin and its reactivation of hyperoxidized peroxiredoxin through reduction of cysteine sulfinic acid in the active site to cysteine. J Biol Chem 279: 50994-51001, 2004.
3. Chevallet M, Wagner E, Luche S, Van DA, Leize-Wagner E, and Rabilloud T. Regeneration of peroxiredoxins during recovery after oxidative stress: only some overoxidized peroxiredoxins can be reduced during recovery after oxidative stress. J Biol Chem 278: 37146-37153, 2003.
4. Dekhuijzen PN, Aben KK, Dekker I, Aarts LP, Wielders PL, van Herwaarden CL, and Bast A. Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 154: 813-816, 1996.
5. Dubuisson M, Vander SD, Clippe A, Etienne F, Nauser T, Kissner R, Koppenol WH, Rees JF, and Knoops B. Human peroxiredoxin 5 is a peroxynitrite reductase. FEBS Lett 571: 161-165, 2004.
6. Golpon HA, Coldren CD, Zamora MR, Cosgrove GP, Moore MD, Tuder RM, Geraci MW, and Voelkel NF. Emphysema lung tissue gene expression profiling. Am J Respir Cell Mol Biol 31: 595-600, 2004.
7. Gromer S, Urig S, and Becker K. The thioredoxin system-from science to clinic. Med Res Rev 24: 40-89, 2004.
8. Hackett NR, Heguy A, Harvey BG, O'Connor TP, Luettich K, Flieder DB, Kaplan R, and Crystal RG. Variability of antioxidant-related gene expression in the airway epithelium of cigarette smokers. Am J Respir Cell Mol Biol 29: 331-343, 2003.
9. Harju T, Kaarteenaho-Wiik R, Soini Y, Sormunen R, and Kinnula VL. Diminished immunoreactivity of gamma-glutamylcysteine synthetase in the airways of smokers' lung. Am J Respir Crit Care Med 166: 754-759, 2002.
10. Hirota K, Murata M, Sachi Y, Nakamura H, Takeuchi J, Mori K, and Yodoi J. Distinct roles of thioredoxin in the cytoplasm and in the nucleus. A two-step mechanism of redox regulation of transcription factor NF-kappaB. J Biol Chem 274: 27891-27897, 1999.
11. Kim H, Lee TH, Park ES, Suh JM, Park SJ, Chung HK, Kwon OY, Kim YK, Ro HK, and Shong M. Role of peroxiredoxins in regulating intracellular hydrogen peroxide and hydrogen peroxide-induced apoptosis in thyroid cells. J Biol Chem 275: 18266-18270, 2000.
12. Kim HS, Manevich Y, Feinstein SI, Pak JH, Ho YS, and Fisher AB. Induction of 1-cys peroxiredoxin expression by oxidative stress in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 285: L363-L369, 2003.
13. Kinnula VL. Focus on antioxidant enzymes and antioxidant strategies in smoking related airway diseases. Thorax 60: 693-700, 2005.
14. Kinnula VL, Lehtonen S, Kaarteenaho-Wiik R, Lakari E, Paakko P, Kang SW, Rhee SG, and Soini Y. Cell specific expression of peroxiredoxins in human lung and pulmonary sarcoidosis. Thorax 57: 157-164, 2002.
15. Kinnula VL, Lehtonen S, Sormunen R, Kaarteenaho-Wiik R, Kang SW, Rhee SG, and Soini Y. Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. J Pathol 196: 316-323, 2002.
16. Lehtonen ST, Markkanen PM, Peltoniemi M, Kang SW, and Kinnula VL. Variable overoxidation of peroxiredoxins in human lung cells in severe oxidative stress. Am J Physiol Lung Cell Mol Physiol 288: L997-1001, 2005.
17. Lehtonen ST, Svensk AM, Soini Y, Paakko P, Hirvikoski P, Kang SW, Saily M, and Kinnula VL. Peroxiredoxins, a novel protein family in lung cancer. Int J Cancer 111: 514-521, 2004.
18. Ohlmeier S, Kastaniotis AJ, Hiltunen JK, and Bergmann U. The yeast mitochondrial proteome, a study of fermentative and respiratory growth. J Biol Chem 279: 3956-3979, 2004.
19. Pak JH, Manevich Y, Kim HS, Feinstein SI, and Fisher AB. An antisense oligonucleotide to 1-cys peroxiredoxin causes lipid peroxidation and apoptosis in lung epithelial cells. J Biol Chem 277: 49927-49934, 2002.
20. Powis G and Montfort WR. Properties and biological activities of thioredoxins. Annu Rev Pharmacol Toxicol 41: 261-295, 2001.
21. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van WC, and Zielinski J. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176: 532-555, 2007.
22. Rabilloud T, Heller M, Gasnier F, Luche S, Rey C, Aebersold R, Benahmed M, Louisot P, and Lunardi J. Proteomics analysis of cellular response to oxidative stress. Evidence for in vivo overoxidation of peroxiredoxins at their active site. J Biol Chem 277: 19396-19401, 2002.
23. Rahman I, van Schadewijk AA, Crowther AJ, Hiemstra PS, Stolk J, MacNee W, and De Boer WI. 4-Hydroxy-2-nonenal, a specific lipid peroxidation product, is elevated in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 166: 490-495, 2002.
24. Rahman I, van Schadewijk AA, Hiemstra PS, Stolk J, van Krieken JH, MacNee W, and De Boer WI. Localization of gamma-glutamylcysteine synthetase messenger rna expression in lungs of smokers and patients with chronic obstructive pulmonary disease. Free Radic Biol Med 28: 920-925, 2000.
25. Tiitto L, Kaarteenaho-Wiik R, Sormunen R, Holmgren A, Paakko P, Soini Y, and Kinnula VL. Expression of the thioredoxin system in interstitial lung disease. J Pathol 201: 363-370, 2003.
26. Wagner E, Luche S, Penna L, Chevallet M, Van DA, Leize-Wagner E, and Rabilloud T. A method for detection of overoxidation of cysteines: peroxiredoxins are oxidized in vivo at the active-site cysteine during oxidative stress. Biochem J 366: 777-785, 2002.
27. Wang X, Phelan SA, Forsman-Semb K, Taylor EF, Petros C, Brown A, Lerner CP, and Paigen B. Mice with targeted mutation of peroxiredoxin 6 develop normally but are susceptible to oxidative stress. J Biol Chem 278: 25179-25190, 2003.
28. Woo HA, Chae HZ, Hwang SC, Yang KS, Kang SW, Kim K, and Rhee SG. Reversing the inactivation of peroxiredoxins caused by cysteine sulfinic acid formation. Science 300: 653-656, 2003.
29. Yang KS, Kang SW, Woo HA, Hwang SC, Chae HZ, Kim K, and Rhee SG. Inactivation of human peroxiredoxin I during catalysis as the result of the oxidation of the catalytic site cysteine to cysteine-sulfinic acid. J Biol Chem 277: 38029-38036, 2002.